Acrylic Acid

Acrylic Acid

SCHEMBL396773

C=CC(=O)NC[N+](C)(C)CCC.C=CC(=O)NC[N+](C)(C)CCC.C=CC(=O)[O-].[Cl-]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Acrylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ZDHHC20 Q5W0Z9 1/20 0.41
ZDHHC2 Q9UIJ5 1/20 0.41
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
BBOX1 O75936 2/20 0.33
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL336794 0.93 ZDHHC20 (0.46) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
SCHEMBL4126549 0.92 ZDHHC20 (0.47) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Bromide SCHEMBL25324391 0.90 ZDHHC20 (0.46) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Chloromethane SCHEMBL28028247 0.88 ZDHHC20 (0.44) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Acrylamide SCHEMBL28870529 0.87 ZDHHC20 (0.41) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
SCHEMBL28180741 0.82 ZDHHC20 (0.37) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
SCHEMBL29142619 0.81 ZDHHC20 (0.53) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Hydrochloric Acid SCHEMBL28470855 0.81 ZDHHC20 (0.57) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Hydrochloric Acid SCHEMBL4534755 0.79 TSHR (0.46) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1
Hydrochloric Acid SCHEMBL27944735 0.78 TSHR (0.42) ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101574-B2 Oligopeptides and compositions containing the oligopeptides COGNIS IP MANAGEMENT GMBH (DE) 2012-01-24 US disclosed
US-7871766-B2 Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant Argania spinosa COGNIS IP MANAGEMENT GMBH (DE) 2011-01-18 US disclosed
US-20100260697-A1 Composition Containing An Extract of the Fruit of Schisandra Chinensis and Process for Producing Same COGNIS FRANCE S.A.S. (FR) 2010-10-14 US disclosed
US-7722901-B2 Uses for the extract of a plant of the family Asclepiadaceae COGNIS IP MANAGEMENT GMBH (DE) 2010-05-25 US disclosed
US-20090075906-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THE OLIGOPEPTIDES COGNIS IP MANAGEMENT GMBH (DE) 2009-03-19 US disclosed
US-20070128302-A1 Composition containing an extract of the fruit of schisandra chinensis and process for producing same COGNIS FRANCE S.A. (FR) 2007-06-07 US disclosed
US-20040042996-A1 Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa COGNIS FRANCE S.A.S. (FR) 2004-03-04 US disclosed
US-20030170298-A1 Proliposomal encapsulated preparations COGNIS IBERIA S.L. (ES) 2003-09-11 US disclosed
US-20030138394-A1 Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa COGNIS FRANCE S.A. (FR) 2003-07-24 US disclosed
US-20030068364-A1 Pro-liposomal encapsulated preparations (iv) COGNIS IBERIA S.L (ES) 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075906-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THE OLIGOPEPTIDES SGMS2, HRH3, CERT1 ZDHHC20 46/4885ZDHHC2 89/4885ALDH1A1 4694/4885
US-20030138394-A1 Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa ARG1, ARG2, CUTA ZDHHC20 1282/4885ZDHHC2 2518/4885ALDH1A1 3916/4885
US-20030068364-A1 Pro-liposomal encapsulated preparations (iv) PHOSPHO1, LIPA, PLIN5 ZDHHC20 1201/4885ZDHHC2 2051/4885ALDH1A1 3463/4885
US-20030170298-A1 Proliposomal encapsulated preparations LIPA, PLIN5, PNLIP ZDHHC20 394/4885ZDHHC2 754/4885ALDH1A1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.